Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) – study protocol for a randomised controlled trial

Table 2 Memantine dosing schedule in mg/day by body weight; study period II

	Dose range (mg/day)^a of distributed medication at … (for weeks …):
Screening/Baseline Weight (kg)	V3 (wk 1)	V4 (wk 2)	V5 (wks 3–4)	V6 (wks 5–8)	V8 (wks 9–12) ^b	V9 (wk 13) (discontinuation)
≥60	5	10	15	15	15	10 → 5 → 0
40–59	5	10	10	10	10	5 → 0
20–39	5	5	5	5	5	5 → 0

Dose titration aims at target doses as indicated in the table, based on clinical judgment.
^aDosage may be adjusted upwards and downwards by 5 mg/day increments within the range shown for each weight group at indicated visits/dates
^bDose should remain stable during the last 4 weeks of study period II (weeks 9–12), unless a dose reduction is necessary for tolerability or safety reasons, based on clinical judgment

ISSN: 1745-6215